Immune Checkpoint Inhibitors (ICIs) in NSCLC: Immune Related Adverse Events (irAEs) and Outcomes. A Canadian Single Institution Experience

Category Primary study
JournalJournal of Thoracic Oncology
Year 2018
This article has no abstract
Epistemonikos ID: 55f821f0735bbfe81bac199c1080039d8f1b2077
First added on: Feb 09, 2025